Rapid Communication

Short-term intravenous interferon therapy for chronic hepatitis B

Hiroaki Okushin, Toru Ohnishi, Kazuhiko Morii, Koichi Uesaka, Shiro Yuasa

AIM: To investigate the therapeutic efficacy of short-term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.

METHODS: IFN-β was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment.

RESULTS: Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%).

CONCLUSION: This 4-wk long IFN-β therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 yr, produced therapeutic effects similar to those achieved by IFN-α or pegylated-IFN-α (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients’ quality of life. IFN-β is administered intravenously, whereas IFN-α is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-β found in this study may be attributed to the multiple doses allowed by the intravenous route.

2008 WJG. All rights reserved.

Key words: Chronic hepatitis B; Hepatitis B e antigen; Hepatitis B virus; Interferon beta; Multiple daily dosing; Short-term treatment; Intravenous injection

Peer reviewers: Philip Abraham, Dr, Professor, Consultant Gastroenterologist & Hepatologist, P. D. Hinduja National Hospital & Medical Research Centre, Veer Savarkar Marg, Mahim, Mumbai 400 016, India; Richard A Rippe, Dr, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7038, United States

Okushin H, Ohnishi T, Morii K, Uesaka K, Yuasa S. Short-term intravenous interferon therapy for chronic hepatitis B. World J Gastroenterol 2008; 14(19): 3038-3043 Available from: URL: http://www.wjgnet.com/1007-9327/14/3038.asp DOI: http://dx.doi.org/10.3748/wjg.14.3038

INTRODUCTION

The increasing prevalence of chronic hepatitis caused by hepatitis B or C virus infection represents a concern in many regions worldwide. Interferons (IFN) are widely used in the treatment of the disease. With the recent launch of lamivudine, adefovir, and entecavir, the number of treatment options for chronic hepatitis B has increased. Treatment with these oral nucleoside analogues has serious drawbacks, such as the development of resistant HBV strains[3,4] and the need for years of treatment[5,6] or even a lifetime therapy. Thus, a large number of patients still require IFN therapy, which is effective in a relatively short period of time. Recently, however, in some patients, the treatment with IFN is often prolonged up to 24-48 wk to improve efficacy[9,10]. IFN-α is administered intramuscularly or subcutaneously and may be associated with such adverse effects as fatigue, insomnia, anorexia, and alopecia[11,12]. These effects presumably result from prolonged elevation of blood IFN levels. Prolonged exposure to higher levels of the circulating drug may produce a greater therapeutic effect while inducing greater adverse effects[13,14]. Treatment for a higher therapeutic effect without consideration of the burden on patients is not a good therapeutic strategy.

In Japan, IFN preparations for the treatment of hepatitis B include IFN-α for intramuscular or subcutaneous administration and IFN-β for intravenous administration[15]. Both IFN-α and IFN-β bind to the an identical IFN receptor and induce PKR and other antiviral proteins via intracellular signal transduction systems represented by JAK/STAT[16,17]. Because of the intravenous route, the blood concentration of IFN-β reaches its peak immediately after infusion and then decreases.

© 2008 WJG. All rights reserved.

Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan
Correspondence to: Hiroaki Okushin, MD, Department of Internal Medicine, Himeji Red Cross Hospital, 1-12-1 Shimoteno, Himeji-shi, Hyogo 670-8540, Japan. hiroaki.okushin@hotmail.co.jp
Telephone: +81-79-2942251 Fax: +81-79-2964050 Received: October 23, 2007 Revised: March 25, 2008
was measured by radioassay. Serum HBV-DNA was radioimmunoassay (RIA). HBV-DNA polymerase activity (PHA), HBeAg and anti-HBe were measured by anti-HBs was measured by passive hemagglutination (PHA), HBeAg and anti-HBe were measured by hematological tests were performed each time. HBsAg was measured by 2-5AS at baseline was 114.8 ± 102.1 (mean ± SD). The levels at wk 1, 2, and at the end of treatment were 389.9 ± 205.3, 333.3 ± 133.4, and 344.3 ± 181.2, respectively.

2-5AS
Figure 2 shows the change in 2-5AS levels. The level of 2-5AS at baseline was 114.8 ± 102.1 (mean ± SD). The levels at wk 1, 2, and at the end of treatment were 389.9 ± 205.3, 333.3 ± 133.4, and 344.3 ± 181.2, respectively.

Adverse effects
No patients discontinued treatment because of adverse effects, with a treatment completion rate of 100%. Fever was mild because antipyretic loxoprofen sodium was administered before intravenous infusion to suppress IFN-α.

RESULTS

Patient population
Clinical characteristics of the 26 patients with HBeAg positive chronic hepatitis B at beginning of the treatment are shown in Table 1. All patients received a total dose of 102 MIU of IFN-β over a period of 28 d, and none of them dropped out because of adverse effects or other reasons.

Clinical outcomes
Six months after the end of IFN administration, loss of HBV-DNA occurred in 13 (50.0%) patients, loss of HBeAg in 9 (34.6%), loss of HBV-DNA and HBeAg in 9 (34.6%), development of anti-Hbe in 10 (38.5%), and HBe seroconversion in 8 (30.8%). The last parameter is a measure of the therapeutic effect, defined by the loss of HBeAg and the subsequent development of anti-HBe. ALT levels normalized in 11 (42.0%) of the 26 patients. The percentage of patients, which became negative for HBV-DNA, HBeAg, and the change in ALT levels during/after the treatment are shown in Table 2 and Figure 1, respectively.

Baseline HBV DNA polymerase activity and virological response
Patients were stratified according to baseline DNA polymerase activity (less than 1000 cpm vs 1000 cpm or more), and virological responses were recorded. Among 15 patients with an activity lower than 1000 cpm, 11 (73.3%) had a complete virological response, and 4 (26.7%) had no response. Among the 11 patients with an activity of 1000 cpm or more, 2 (18.2%) had a complete virological response, and 9 (81.8%) had no response.

Adverse effects
No patients discontinued treatment because of adverse effects, with a treatment completion rate of 100%. Fever was mild because antipyretic loxoprofen sodium was administered before intravenous infusion to suppress IFN-α.

Materials and methods
Patients
Among Japanese adult patients with chronic hepatitis B who were positive for HBeAg and HBV-DNA and presented at our hospital from 1996 to 2002, 26 patients were enrolled in this open-label study. The study was conducted in accordance with the Declaration of Helsinki, and the patients consented to the experimental treatment of hepatitis B. Inclusion criteria were: age of 20 years or older, blood HBeAg positivity, blood HBV-DNA positivity, and persistent abnormal elevation of ALT levels. Exclusion criteria included: coinfection with hepatitis C virus or HIV, presence of hepatocellular carcinoma, symptoms caused by decompensated cirrhosis, alcoholic, autoimmune, drug-induced, or other non-viral liver disorders, and hypersensitivity to IFN-α.

Treatment methods
Human fibroblast-derived natural IFN-β (FERON®, Toray Industries Inc., Japan) was used; 1 to 3 MIU was dissolved in 100 mL of 5% glucose or isotonic saline solution for injection and infused intravenously for about 10 minutes. The dosing schedule comprised 2 MIU in the morning and 1 MIU in the evening (twice daily) at d 1 of treatment, 3 MIU in the morning and evening (twice daily) from d 2 through d 7, and 1 MIU each in the morning, in the afternoon, and at bedtime (thrice daily) from d 8 to d 28, with a total dose of 102 MIU administered over a treatment period of 28 d. Patients were followed up for 24 wk after the end of the IFN-β therapy.

Laboratory methods
Blood samples were collected immediately before the start of treatment, weekly during the treatment, and monthly during the follow-up period. Biochemical and hematological tests were performed each time. HBsAg was measured by reversed passive hemagglutination (R-PHA), anti-HBs was measured by passive hemagglutination (PHA), HBeAg and anti-HBe were measured by radioimmunoassay (RIA). HBV-DNA polymerase activity was measured by radioassay. Serum HBV-DNA was measured by branched DNA probe assay (Chiron Corp, USA) with a detection sensitivity of 0.70 megaequivalents (Meq) per milliliter. Anti-hepatitis C virus antibodies were measured by enzyme immunoassay (EIA). In addition, 2’-5’-oligoadenylate synthetase (2-5AS), an indicator of IFN activity, was quantitatively measured by RIA.

Statistical analysis
Values are given as either mean ± SD or median and range. For comparison, Student’s t-test or the Chi-square test were used. Statistical tests were two-sided, and a P value of less than 0.05 was considered as statistically significant.
induced fever. During treatment with IFN, no patients experienced depression. There was no proteinuria, severe thrombocytopenia or leukopenia (as shown in Figure 3).

**DISCUSSION**

Approximately 10 years ago, the IFN therapy for chronic hepatitis B was administered for up to 4 wk in Japan. However, a 24-wk regimen has been recently used because a longer treatment seems to improve the efficacy. In the present study, we used a short-term, intravenous therapy of 4 wk, which seems to be against the recent recommendations for long-term regimens. However, 4-wk multiple daily dosing of intravenous IFN-β used in our study produced therapeutic effects similar to those achieved by 12-wk or 24-wk IFN-α or 48-wk peg-IFN-α, which are indicated by the American Association for the Study of Liver Diseases\(^{[18,19]}\). The HBe seroconversion rate with IFN-β in this study was 31%, which was higher than the reported 12-18% with IFN-α\(^{[18,20]}\), lamivudine\(^{[18,21-23]}\), or adefovir\(^{[19,24]}\), and which was almost equal to that achieved by a 48-wk therapy with peg-IFN-α\(^{[25]}\) (Table 3). In the United States, the distribution of HBV genotypes was reported as genotypes A (33%), B (21%), C (34%), D (9%), E (1%), F (1%), and G (1%)\(^{[26]}\). Given that the majority (about 80%) of Japanese patients infected with HBV has IFN-resistant genotype C\(^{[27]}\), the multiple daily dosing of intravenous IFN-β used in this study appears to be a beneficial treatment.

### Table 1 Clinical characteristics at the beginning of the treatment

| Characteristics   | Baseline          |
|-------------------|-------------------|
| Age (yr)          | 31.8 ± 7.0        |
| Sex (male/female) | 19/7              |
| ALT (U/L)         | 246.9 ± 154.2     |
| HBV DNA (≥ 10/ < 10 Meq/mL) | 16/10  |
| HBV DNA polymerase (cpm) | 750.5 (10-10^710) |
| PLT (* 10^4/mm^3) | 19.3 ± 10.7       |

1 mean ± SD; 2 Median (range).

### Table 2 Response rate in patients with HBeAg positive chronic hepatitis B by interferon-β treatment (%)

| Mesures                              | wk 1                  | wk 2                  | End of the treatment | 6 mo after treatment |
|--------------------------------------|-----------------------|-----------------------|----------------------|----------------------|
| HBV-DNA negative                    | 5/26 (19.2)           | 5/26 (19.2)           | 10/26 (38.5)         | 13/26 (50.0)         |
| HBeAg and HBV-DNA negative          | 4/26 (15.4)           | 9/26 (34.6)           |                      |                      |

### Table 3 Comparison of response rates in patients with HBeAg positive chronic hepatitis B at 6 mo after the treatment (%)

| Measures                              | INF-β (iv) 4 wk | INF-α (sc or im) 12-24 wk | Lamivudine 1 yr | Adefovir dipivoxil 48 wk | Pegylated interferon-α 48 wk |
|--------------------------------------|----------------|---------------------------|----------------|--------------------------|----------------------------|
| Loss of serum HBV DNA                | 50             | 37                        | 44             | 21                       | 32                        |
| Loss of HBeAg 35                     | 35             | 33                        | 17-32          | 24                       | 34                        |
| Normalization of ALT                 | 42             | Difference of 18          |                |                          |                           |
| Loss of HBsAg 80                     | 8              | <1                        | 0              | 3                        |
| Histological improvement             | 40             | Difference of 23          |                |                          |                           |
| Durability of the response           | 80-90          | 50-80                     |                |                          | 82                        |

www.wjgnet.com
Our results suggest that HBV DNA polymerase activity at baseline before the treatment may be used to predict the therapeutic effect of IFN to some degree. Multiple daily dosing of IFN-β may be the regimen of first-line choice in patients with baseline HBV DNA polymerase activity less than 1000 cpm because 73.3% of those patients had a complete virological response. We believe that the direct antiviral effect of IFN on HBV is enough to achieve a complete response in those patients, whereas an appropriate host immune response are also needed in patients with a polymerase activity of 1000 cpm or more indicating rapid proliferation of HBV. A typical example is shown in Figure 4. The patient had an HBV DNA polymerase activity of 1338 cpm and an HBV-DNA level of 710 Meq/mL before the IFN therapy. After the end of IFN-β administration, an increase in HBV-DNA and subsequent rapid increase in ALT levels (so-called Schub) occurred, followed by the loss of HBeAg, HBV-DNA, and DNA polymerase, normalization of ALT levels, and development of anti-HB. The rapid increase in ALT levels probably resulted from the host’s immune response to the rapid increase in the HBV proliferation following the regimen and the subsequent rapid elimination of infected hepatocytes in an appropriate manner.

Our dosing regimen had a good safety profile with a low incidence of mild adverse effects and no serious adverse effects. This may be attributed to lower daily doses of 3 MIU from d 8 onward and a short treatment period of 1 mo. Although platelet and leukocyte counts decreased at wk 1 compared with baseline levels, the counts remained unchanged thereafter until the end of treatment and almost returned to baseline levels after completion of therapy. Our previous experience suggested that thrombocytopenia and proteinuria should be closely monitored during treatment with IFN-β at doses of 3 MIU twice daily. However, cytopenia did not worsen because of switching to 1 MIU thrice daily from d 8. The levels of 2-5AS in blood (mean ± SD) at baseline and wk 1, 2, and 4 of treatment were 133.9 ± 122.2, 445.0 ± 209.7, 335.0 ± 139.9, and 387.8 ± 200.7, respectively, and remained elevated during treatment, suggesting that the dose regimen produced a potent and durable antiviral effect despite a modest cytopenia.

In general, the pharmacokinetics of an intravenously administered drug are characterized by a higher blood elimination rate, higher peak blood concentration, and greater tissue distribution than an intramuscularly administered drug, and these are also true of IFN. Different types of IFN formulations are available for therapy, and human fibroblast IFN-β is applicable to intravenous administration for the treatment of hepatitis in Japan.

We chose intravenous administration and multiple daily dosing because of the following three reasons. First, intravenously administered IFN-β is rapidly eliminated from the blood and below the detection limit shortly after administration[13]. Compared with intramuscularly or subcutaneously administered IFN-α, IFN-β accumulates to a lesser degree and is likely to have less adverse effects[28]. Second, blood concentrations of IFN administered intravenously in multiple daily doses fluctuate with high blood levels and rapid elimination rates. Accordingly, this regimen is likely to avoid persistently elevated blood IFN levels and resultant downregulation of the IFN receptor[14-16], which is likely to occur after intramuscular or subcutaneous administration. The avoidance of the receptor downregulation allows effective binding of IFN and its receptor, and triggers the host defense mechanisms a few times a day to eliminate the virus. Third, the drug administered intravenously is more extensively distributed into organs than that administered intramuscularly. For elimination of HBV present in hepatocytes, intravenous dosing is considered as an effective route of administration, which allows extensive delivery of IFN to the liver. When IFN-α, which was induced by treating human leukocytes with the Sendai virus, was administered intravenously or intramuscularly to rats, IFN-α was detectable in the liver at 10 and 30 min but not at 1 h after intravenous administration whereas IFN levels remained below the detection limit for 4 h in rats receiving an intramuscular administration[29]. In patients with hepatitis, a transient increase in ALT levels is often observed after intravenous administration of IFN[30]. Because IFN distributes in the liver at high concentrations after intravenous administration, extensive loss of infected hepatocytes may occur, resulting in an increase in ALT levels.

When IFN or any other cytokine that exerts a pharmacological effect via receptor binding is administered, it is important to choose an appropriate route of administration that ensures effective delivery of the drug to the target-cells. An ideal pharmacokinetic profile should include a rapid increase to effective blood concentrations and a rapid elimination after receptor binding to avoid downregulation of the receptor. We believe that intravenous IFN therapy can also be used effectively for the treatment of other diseases including cancer, infection with HIV, and SARS. However, intravenous IFN is now available only in Japan. For further promotion of research on the establishment of intravenous IFN therapy as a convenient, general way of treating these diseases,
intravenous IFN should preferably be available in other countries.

Oral nucleoside analogues, such as lamivudine, adefovir, and entecavir, have a potenti effect in suppressing hepatitis B virus; however, most patients relapse and become positive for the virus after discontinuation of treatment. Thus, these drugs should be taken for a few years or the rest of patients’ lives. These agents also cause problems including development of resistant strains and fetotoxicity, which discourages physicians from administering these agents in pregnant, parturient, and nursing women. Meanwhile, IFN therapy tends to continue for more than 6 months, and increased adverse effects associated with prolonged therapy have become a significant problem. In Japan, both physicians and patients have great difficulty coping with these problems and they are waiting for new effective treatments that ensure improvement in the quality of life for patients.

Short-term treatment with multiple daily dosing of IFN-β in the present pilot study has fewer adverse effects, good therapeutic effects, and reproducibility to some degree. Further studies and randomized clinical trials are required to confirm our promising results.

### REFERENCES

1. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. *J Hepatol* 1997; 26: 1393-1395
2. Hoofnagle JH. Therapy of viral hepatitis. *Digestion* 1998; 59: 563-578
3. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *Gastroenterology* 2000; 119: 172-180
4. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Conodrea LD, Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of treatment. *Hepatology* 2001; 33: 1527-1532
5. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kittis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999; 30: 238-243
6. Sakai T, Shiraki K, Inoue H, Okano H, Deguchi M, Sugimoto K, Ohmori S, Murata K, Nakano T. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C. *Int J Mol Med* 2002; 10: 201-204
7. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandeet T, Chutapatui A, Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. *J Viral Hepat* 2003; 10: 298-305
8. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon alpha-2b treatment for hepatitis B e antigen-positive chronic hepatitis B. *Ann Intern Med* 1995; 122: 664-675
9. Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmun thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. *Dig Dis Sci* 2002; 47: 562-563
10. Lambotte O, Gelu-Simeon M, Maingi G, Koth B, Buffet C, Delfraissy JF, Gujard C. Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. *J Infect* 2005; 51: e113-e115
11. Suzuki F, Arase Y, Akuta N, Tsubota A, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Sato J, Kumada H. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. *J Gastroenterol* 2004; 39: 969-974
12. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. *Annu Rev Biochem* 1998; 67: 227-264
13. Hino K, Kondo T, Yasuda K, Fukuhara A, Fujikawa S, Shimoda K, Niwa H, Iino S, Suzuki H. Pharmacokinetics and biological effects of beta interferon by intravenous (iv) bolus administration in healthy volunteers as compared with iv infusion. *Jpn Clin Pharmacol Ther* 1998; 16: 625-635
14. Lau AS, Hannigan GE, Freedman MH, Williams BR. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. *J Clin Invest* 1986; 77: 1632-1638
15. Nakajima S, Kuroki T, Kurai O, Kobayashi K, Yamamoto S. Interferon receptors during treatment of chronic hepatitis B
with interferon. J Gastroenterol Hepatol 1989; 4: 419-427

16 Nakajima S, Kuroki T, Shintani M, Kurai O, Takeda T, Nishiguchi S, Shiomi S, Seki S, Kobayashi K. Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. Hepatology 1990; 12: 1261-1265

17 Okushin H, Morii K, Kishi F, Yuasa S. Efficacy of the combination therapy using twice-a-day IFN-beta followed by IFN-alpha-2b in treatment for chronic hepatitis C. Kanzo 1997; 38: 11-18

18 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241

19 Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861

20 Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323

21 Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu FC, Den J, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68

22 Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hahn HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263

23 Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568

24 Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsbohn MS, Xiong S, Fry J, Brosgraff CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816

25 Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695

26 Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35: 1274-1276

27 Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-594

28 Festi D, Sandri L, Mazzella G, Roda E, Saccò T, Staniscia T, Capodicasa S, Vestito A, Colecchia A. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004; 10: 12-16

29 Mura N, Matsuzawa H, Ueda H, Sakashita K, Nakamura K, Uemura H, Arawa S, Hananaka N, Chisaka T, Yagi N, Araki H, Koga J, Matsuo A. Pharmacokinetics of FPI-31. Jpn Pharmacol Ther 1993; 21: 2211-2226

30 Fujimori K, Mochida S, Matsu S, Ohno A, Fujiwara K. Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients. J Gastroenterol Hepatol 2002; 37: 40-46

S-Editor Piscaglia AC L-Editor Rippe R E-Editor Lu W